The Impact of COVID-19 on CAD Patient Management

Like many of you I expect, I have been thinking quite a bit about how providers can best triage and manage patients with suspected coronary artery disease (CAD) during this incredibly difficult time of COVID-19. Based on the statistics coming out of Wuhan, China, we know that more than 40% of COVID-19 patients have cardiovascular disease.1 We also know of course that CAD isn’t going away. In fact, while more than 3,000 people in China have died to date from COVID-19, it’s been reported that approximately 5,000 people are dying daily due to ischemic heart disease in China.2

As I’ve been talking to many of you over these past few weeks, I realized all are grappling with the same questions, including:

To address these critical questions, we convened a panel of esteemed experts for a webinar. The panel included Drs. Michael Poon and Michael Kim from Northwell Health’s Lenox Hill in NYC, who shared their first-hand experience being in an epicenter of the pandemic; Dr. Fred Welt from University of Utah, who was lead author on the ACC/SCAI guidance on considerations for the cath lab; and Dr. Geoff Rose from Sanger Heart & Vascular Institute, who provided important insights from an overall healthcare system perspective. Here’s what I learned:

If you would like to listen to highlights from the webinar, you can find them here. Best wishes to all of our colleagues for health and safety!

Get the Highlights

Note: The comments have been paraphrased for clarity and are not direct quotes.

— A perspective from HeartFlow Chief Medical Officer, Campbell Rogers, MD
Bio | LinkedIn

1. Chen, et al., The Lancet, 2020
2. Jones, D., NEJM, 2020.

Contact Us

*Required fields

Request the HeartFlow Analysis Near You

If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.

*Required fields

残念ながら、GDPR 規制により、この Web フォームを通じて求人への応募やキャリアに関する問い合わせを受け付けることはできません。弊社を通じてお申込みください 採用ページ. ご関心をお寄せいただきありがとうございます!


HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用​​することを目的としています。


さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.

The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.

For additional indication information about the HeartFlow Analysis, please visit

If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.

Please apply for research grants through our online submission form.

Unfortunately, we cannot take job applications or career inquiries through this web form due to GDPR regulations. Please apply through our Careers Page. Thank you for your interest!

Campbell Rogers, M.D., F.A.C.C.

Executive Vice President and Chief Medical Officer

Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.

He received his A.B. from Harvard College and his M.D. from Harvard Medical School.